Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/21/2008

eriod in 2007.

Revenues under collaborative agreements were $18.5 million for the quarter ended March 31, 2008, which includes cost-sharing payments of $17.4 million, compared to $10.0 million, which includes cost-sharing payments of $8.9 million for the same period in 2007. The increase primarily reflects higher cost-sharing payments from Eli Lilly and Company to equalize development expenses for exenatide once weekly and BYETTA.

Selling, general and administrative expenses were $98.2 million for the quarter ended March 31, 2008, compared to $87.8 million for the same period in 2007. The increase primarily reflects promotional expenses for BYETTA, SYMLIN, exenatide once weekly market development and increases in infrastructure to support the Company's growth.

Research and development expenses increased to $77.2 million for the quarter ended March 31, 2008, compared to $59.6 million for the same period in 2007. The increase primarily reflects increased expenses for once weekly exenatide, and investment in the Company's early-stage obesity programs and drug delivery capabilities. Non-GAAP, net research and development expenses net of cost-sharing payments increased to $59.8 million for the quarter ended March 31, 2008, compared to $50.7 million for the same period in 2007.

Collaborative profit sharing, which represents Lilly's share of the gross margin for BYETTA, was $69.9 million for the quarter ended March 31, 2008, compared to $66.9 million for the same period in 2007.

Interest and other income, net decreased to $1.3 million for the quarter ended March 31, 2008, compared to $8.1 million for the same period in 2007. The decrease primarily reflects higher interest expense due to the Company's $575 million convertible debt issuance in June 2007 and the Company's $125 million term loan entered into in December 2007.

Net loss for the quarter ended March 31, 2008 was $68.8 million, or $0.51 per share, compared to $49.4 million,
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... fitness site and the largest online retailer of nutritional supplements, has officially ... is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, ... contract lifecycle management solution, as well as announced the date of its next ... and ease of contract management tasks as well as enhancements to the customer ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Care and U.S. Soccer Federation team up to give ... a performance edge with better vision, JACKSONVILLE, Fla., March ... of ACUVUE(R) Brand Contact Lenses,today announced it is an official ... for the sport of soccer in the United,States., Under ...
... ANSYS, Inc.,(Nasdaq: ANSS ), a global innovator ... development processes, today announced it is a,sponsor of ... Carnegie Museum of,Natural History in Pittsburgh. This is ... scientifically accurate, immersive environments that are,composed of original ...
... Inc. (NYSE: HB ) (the "Company") announced today ... offer to purchase,any and all of its outstanding 4.50 ... $250 million in aggregate principal amount was,outstanding as of ... to an Offer to Purchase dated February 29, 2008 ...
... COM, VANCOUVER, March 17 /PRNewswire-FirstCall/ - ... positive interim clinical results,from its 90-day Phase ... analysis,demonstrated statistically significant efficacy for the patient ... compared to placebo. The,safety data from the ...
... Researchers will unveil a,new brain fitness training ... numerous,published studies to help people maintain health-related ... daily living tasks essential to,independence. The research ... neuroscience company, will introduce the new program, ...
... An investigational antiviral drug currently undergoing human trials ... potential to reduce muscle cell damage in Duchenne and ... led by Cincinnati Childrens Hospital Medical Center reported their ... a letter posted online March 16 by the journal ...
Cached Medicine News:Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 2Health News:U.S. Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 2Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 3Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 4Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 5Health News:Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor 6Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 2Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 3
(Date:8/3/2015)... PAUL, Minn. , Aug. 3, 2015  EnteroMedics ... using neuroblocking therapy to treat obesity, metabolic diseases and ... McDougal has been appointed to the Board of ... as a Class II Director until the 2018 annual ... Ms. McDougal has served in an executive ...
(Date:8/2/2015)... 2015 Mandatory takeover offer ... ("Dechra" or the "Company") is pleased to announce the ... Mr. Marijan Han žeković to acquire his 63.3% ... ("Genera"), a Croatian listed pharmaceutical business.   ... equivalent to €51.4 million for the entire share capital ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
DePuy's Shoe Boots are sealed thermoplastic boots that help provide splash protection from microorganisms, particulate matter and body fluids....
... System rede phines sharpness and efficiency ... for penetrating keratoplasty. Advanced trephine blade ... to achieve the critical fit needed for ... fully customized system enables surgeons to select ...
The MP-1 Microperimeter delivers an accurate, fully automatic assessment of the macular function. This is achieved by effectively integrating in a single instrument the objectivity of fundus imaging ...
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts....
Medicine Products: